S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
LON:RUA

RUA Life Sciences (RUA) Share Forecast, Price & News

GBX 40.25
+0.25 (+0.63%)
(As of 05/23/2022 03:33 PM ET)
Add
Compare
Today's Range
38.90
40.52
50-Day Range
40
51
52-Week Range
38.85
168
Volume
55,865 shs
Average Volume
42,035 shs
Market Capitalization
£8.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive RUA News and Ratings via Email

Sign-up to receive the latest news and ratings for RUA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

RUA Life Sciences logo

About RUA Life Sciences

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
32
Year Founded
N/A

Sales & Book Value

Annual Sales
£1.61 million
Cash Flow
GBX 21.50 per share
Book Value
GBX 32.70 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£8.93 million
Optionable
Not Optionable

Company Calendar

Today
5/23/2022
Next Earnings (Estimated)
7/11/2022

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













RUA Life Sciences (LON:RUA) Frequently Asked Questions

When is RUA Life Sciences' next earnings date?

RUA Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, July 11th 2022.
View our earnings forecast for RUA Life Sciences
.

Who are RUA Life Sciences' key executives?
RUA Life Sciences' management team includes the following people:
  • Mr. John McKenna, Director of Clinical Marketing & Exec. Director (Age 69, Pay $52.25k)
  • Dr. Caroline Stretton, Group MD & Director (Age 51, Pay $108.68k)
  • Lachlan Smith, CFO & Director
  • Mr. Ajay Padsalgikar, Chief Scientific Officer
  • Mr. Iain Anthony, Director of Clinical & Regulatory Affairs and Director
  • K. M. Full FCCA, Company Sec.
What is RUA Life Sciences' stock symbol?

RUA Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "RUA."

How do I buy shares of RUA Life Sciences?

Shares of RUA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is RUA Life Sciences' stock price today?

One share of RUA stock can currently be purchased for approximately GBX 40.25.

How much money does RUA Life Sciences make?

RUA Life Sciences has a market capitalization of £8.93 million and generates £1.61 million in revenue each year.

How many employees does RUA Life Sciences have?

RUA Life Sciences employs 32 workers across the globe.

What is RUA Life Sciences' official website?

The official website for RUA Life Sciences is www.rualifesciences.com.

How can I contact RUA Life Sciences?

The company can be reached via phone at 44 1294 317073.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.